Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

AZN

Astrazeneca plc ADR

Jun 14 • 02:55PM ET

79.37

Dollar change -0.16
Percentage change -0.20	%

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX	P/E	39.12	EPS (ttm)	2.03	Insider Own	0.02%	Shs Outstand	3.10B	Perf Week	-0.81%
Market Cap	246.09B	Forward P/E	16.94	EPS next Y	4.69	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	3.12%
Income	6.33B	PEG	2.88	EPS next Q	1.01	Inst Own	16.04%	Short Float	0.22%	Perf Quarter	19.70%
Sales	47.61B	P/S	5.17	EPS this Y	12.08%	Inst Trans	-2.06%	Short Ratio	1.31	Perf Half Y	20.44%
Book/sh	12.63	P/B	6.29	EPS next Y	15.16%	ROA	6.36%	Short Interest	6.67M	Perf Year	9.07%
Cash/sh	2.59	P/C	30.68	EPS next 5Y	13.60%	ROE	17.29%	52W Range	60.47 - 80.86	Perf YTD	17.85%
Dividend Est.	1.55 (1.95%)	P/FCF	29.02	EPS past 5Y	17.72%	ROI	9.64%	52W High	-1.84%	Beta	0.47
Dividend TTM	1.45 (1.83%)	Quick Ratio	0.70	Sales past 5Y	16.24%	Gross Margin	73.81%	52W Low	31.26%	ATR (14)	1.00
Dividend Ex-Date	Feb 22, 2024	Current Ratio	0.89	EPS Y/Y TTM	34.54%	Oper. Margin	17.50%	RSI (14)	58.43	Volatility	0.88% 1.03%
Employees	89900	Debt/Eq	0.92	Sales Y/Y TTM	8.60%	Profit Margin	13.30%	Recom	1.72	Target Price	85.49
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	20.85%	Payout	73.87%	Rel Volume	0.31	Prev Close	79.53
Sales Surprise	7.47%	EPS Surprise	7.80%	Sales Q/Q	16.55%	Earnings	Apr 25 BMO	Avg Volume	5.08M	Price	79.37
SMA20	0.95%	SMA50	5.83%	SMA200	16.36%	Trades		Volume	1,304,854	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy	$75
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight

Show Previous Ratings

Today 08:02AM	Adobe Inc. (NASDAQ:ADBE) Q2 2024 Earnings Call Transcript (Insider Monkey)
Jun-13-24 11:20AM	AstraZeneca CFO: 'We've come a long way in our oncology portfolio' (Yahoo Finance)
10:11AM	FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D (Zacks)
08:00AM	Why It's A New Day For COPD Patients And Regeneron, Sanofi, Verona Stocks (Investor's Business Daily)
04:32AM	FDA approves AstraZenecas Farxiga for paediatric T2D patients (Pharmaceutical Technology)
05:35PM	Loading…
Jun-12-24 05:35PM	FARXIGA approved in the US for the treatment of pediatric type-2 diabetes (Business Wire)
08:13AM	AstraZeneca champions early kidney disease diagnosis with modelling data (Pharmaceutical Technology)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
Jun-11-24 12:58PM	Why AstraZeneca plc (NASDAQ:AZN) is Investors' One of Favorite International Dividend Stock? (Insider Monkey)
11:04AM	12 Best International Dividend Stocks to Buy Now (Insider Monkey)
06:00AM	Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (News Direct)
Jun-10-24 06:15PM	Astrazeneca (AZN) Advances But Underperforms Market: Key Facts (Zacks)
04:38PM	Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks (Investor's Business Daily)
09:42AM	AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag (Zacks)
07:00AM	TAGRISSO (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer (Business Wire)
05:04AM	Loading…
05:04AM	Most CEOs are defeating attempts to vote down their pay. Can Tesla's Elon Musk do the same? (Yahoo Finance)
Jun-07-24 04:13PM	The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now (InvestorPlace)
Jun-06-24 07:00AM	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer (PR Newswire)
07:00AM	Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate (InvestorPlace)
Jun-05-24 04:25AM	AstraZeneca completes Fusion Pharmaceuticals acquisition (Pharmaceutical Technology)
Jun-04-24 08:00PM	We're in a difficult business but have the right level of confidence, says AstraZeneca CEO (CNBC TV)
08:00PM	AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer (CNBC TV)
07:00AM	AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 (PR Newswire)
04:25AM	EMA CHMP recommends AstraZenecas Tagrisso for lung cancer (Pharmaceutical Technology)
Jun-03-24 06:15PM	Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:26PM	Hedge Funds are Bullish on This Gene Therapy Stock (Insider Monkey)
10:53AM	Cramer's Stop Trading: AstraZeneca (CNBC TV)
09:00AM	The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. (Motley Fool)
Jun-02-24 02:32PM	TAGRISSO (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial (Business Wire)
08:05AM	IMFINZI (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo (Business Wire)
08:00AM	Loading…
08:00AM	Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives. (The Wall Street Journal)
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy (Business Wire)
06:00AM	3 No-Brainer Stocks to Buy in June (Motley Fool)
04:00AM	With new Enhertu data, an ADC could overtake chemo in breast cancer (BioPharma Dive)
04:00AM	AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer (BioPharma Dive)
May-31-24 12:20PM	The Most Profitable Biotechnology Company in the World (Insider Monkey)
09:41AM	AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030 (The Wall Street Journal)
May-30-24 07:00AM	This Pharma Stock Is Poised to Keep Outperforming the S&P 500 (Motley Fool)
07:00AM	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig (PR Newswire)
04:39AM	Goldman Sachs Says Buy European Pharma Stocks Touting Innovation (Bloomberg)
May-29-24 02:51PM	Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug (Benzinga)
10:51AM	AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal (Zacks)
10:39AM	Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol in phase 1 test (FierceBiotech.com)
10:07AM	AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock (Motley Fool)
08:06AM	AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? (Motley Fool)
May-28-24 04:32PM	Why Is AstraZeneca Stock Trading Lower On Tuesday? (Benzinga)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 06:58PM	This Biotech Stock is a 'Strong Buy' According to Raymond James (Insider Monkey)
06:55PM	Hedge Funds are Racking Up Shares of This Healthcare Stock (Insider Monkey)
06:47PM	Is Insmed Incorporated (NASDAQ:INSM) a Buy According to Hedge Funds? (Insider Monkey)
06:43PM	Hedge Funds are Bullish on This Cancer Stock (Insider Monkey)
06:34PM	Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI) (Insider Monkey)
06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
09:45AM	Here's Why Astrazeneca (AZN) is a Strong Growth Stock (Zacks)
07:00AM	Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial (Business Wire)
06:26AM	AstraZeneca and Daiichi Sankyos ADC improves survival in NSCLC trial (Clinical Trials Arena)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-24-24 07:00AM	AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting (PR Newswire)
05:00AM	Ozempic knockoffs, Pfizer's cost-cutting, and AstraZeneca's future: Pharma news roundup (Quartz)
May-23-24 02:53PM	Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity (Benzinga)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
08:54AM	AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody (Pharmaceutical Technology)
07:00AM	AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) (Business Wire)
05:59AM	AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies (FierceBiotech.com)
May-22-24 07:23PM	Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies (PR Newswire)
05:17PM	Top 20 Largest Publicly Traded Healthcare Companies (Insider Monkey)
11:45AM	Why Astrazeneca (AZN) is a Great Dividend Stock Right Now (Zacks)
09:40AM	AstraZeneca joins obesity biotech SixPeaks at basecamp with $80M for buyout option (FierceBiotech.com)
07:00AM	AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 (Business Wire)
06:58AM	AstraZeneca targets $80bn revenue by 2030 (Pharmaceutical Business Review)
05:34AM	SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca (BioPharma Dive)
May-21-24 05:41PM	AstraZeneca Rises to Record High After Announcing Plans for 'New Era of Growth' (Investopedia)
04:27PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
01:45PM	AstraZenecas $80B sales plan leans on cancer drug expansion (BioPharma Dive)
12:32PM	AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030 (Zacks)
12:15PM	European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030 (MT Newswires)
10:13AM	AstraZeneca aims increase its annual revenue by 75% in its post-COVID era (Quartz)
09:10AM	Sector Update: Health Care Stocks Steady Premarket Tuesday (MT Newswires)
08:24AM	AstraZeneca sets sights on $80B in revenue by 2030 (BioPharma Dive)
08:13AM	AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D (FierceBiotech.com)
08:08AM	Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:00AM	Midday movers: Microsoft, Xpeng rise; Palo Alto, Keysight fall (Investing.com)
07:48AM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:21AM	AstraZeneca Targets $80 Billion Revenue by 2030, Expects to Launch 20 New Medicines (MT Newswires)
04:01AM	AstraZeneca to establish $1.5bn ADC production site in Singapore (Pharmaceutical Technology)
03:51AM	AstraZenecas Revenue Target Signals Pipeline Momentum (The Wall Street Journal)
03:17AM	AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion (The Wall Street Journal)
03:15AM	AstraZeneca shares rise as pharma group unveils 2030 revenue target (Investing.com)
02:14AM	AstraZeneca aims for $80 billion in total revenue by 2030 (Reuters)
02:00AM	AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 (Business Wire)
May-20-24 11:25PM	European stocks fall on Fed rate concerns; AstraZeneca lifts revenue target (Investing.com)
04:38PM	Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population (Benzinga)
04:18PM	Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute (Benzinga)
10:45AM	AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore (Zacks)
06:47AM	Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results (MT Newswires)
05:21AM	AstraZeneca to build $1.5bn ADCs facility in Singapore (Investment Monitor)
04:22AM	Pfizer wins cancer drug patent case against AstraZeneca (Pharmaceutical Technology)
04:11AM	AstraZeneca to Build $1.5 Billion Cancer Therapy Manufacturing Facility in Singapore (MT Newswires)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience